Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT00968968 |
| Title | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone |
| Recruitment | Terminated |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | CAN |